Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006276 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Tolerability, and Safety Study of DFN-15
A Phase 3 study, sponsored by BioDelivery Sciences International.
- Completed
- Registry status
- Phase 3
- Development phase
- 622
- Enrollment target
NCT03006276 is a Phase 3 study that has completed, run by BioDelivery Sciences International. The registered enrollment target is 622 participants.
The verdict
NCT03006276, a Phase 3 study, has completed, sponsored by BioDelivery Sciences International.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 622 participants
- Enrollment target
Study Summary
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
Interventions
- DRUG DFN-15 Active
- OTHER DFN-15 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03006276
The ClinicalTrials.gov registry entry for NCT03006276 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 622 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioDelivery Sciences International, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DFN-15 Active is the first listed.
NCT03006276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03006276 about?
NCT03006276 is a clinical study titled "Efficacy, Tolerability, and Safety Study of DFN-15". Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
What is the current status of trial NCT03006276?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 622 participants. The study started on 2016-12. Estimated completion is 2019-05.
What interventions are being tested in trial NCT03006276?
The interventions under investigation include: DFN-15 Active (DRUG), DFN-15 Placebo (OTHER).
Who is sponsoring clinical trial NCT03006276?
This trial is sponsored by BioDelivery Sciences International, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.